<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type='text/xml' href='//dbv-technologies.com/?wds_sitemap_styling=1&#038;template=sitemapBody'?><!-- SMARTCRAWL SITEMAP -->
<urlset
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd http://www.google.com/schemas/sitemap-image/1.1 https://www.google.com/schemas/sitemap-image/1.1/sitemap-image.xsd"
	xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
	>
			<url>
<loc>https://dbv-technologies.com/resource/safety-of-epicutaneous-immunotherapy-in-peanut-allergic-children-realise-randomized-clinical-trial-results/</loc>
<lastmod>2023-04-05T05:35:01+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/reduction-in-peanut-reaction-severity-during-oral-challenge-after-12-months-of-epicutaneous-immunotherapy/</loc>
<lastmod>2023-04-05T05:49:10+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/predicted-number-of-peanut-allergic-patients-needed-to-treat-with-epicutaneous-immunotherapy-epit-to-prevent-one-allergic-reaction-a-novel-approach-to-assessing-relevance/</loc>
<lastmod>2023-04-05T05:50:39+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/sustained-unresponsiveness-to-peanut-after-long-term-peanut-epicutaneous-immunotherapy/</loc>
<lastmod>2023-04-05T05:57:21+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/post-hoc-analysis-of-epicutaneous-immunotherapy-for-peanut-allergy-phase-3-results/</loc>
<lastmod>2023-04-05T05:58:44+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/improvements-in-quality-of-life-in-children-following-epicutaneous-immunotherapy-epit-for-peanut-allergy-in-the-pepites-and-people-studies/</loc>
<lastmod>2023-04-05T05:59:51+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/long-term-open-label-extension-study-of-the-efficacy-and-safety-of-epicutaneous-immunotherapy-for-peanut-allergy-in-children-people-3-year-results/</loc>
<lastmod>2023-04-05T06:10:29+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/improvements-in-eliciting-dose-across-baseline-sensitivities-following-12-months-of-epicutaneous-immunotherapy-epit-in-peanut-allergic-children-aged-4-to-11-years/</loc>
<lastmod>2023-04-05T06:33:18+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/an-evaluation-of-factors-influencing-response-to-epicutaneous-immunotherapy-for-peanut-allergy-in-the-pepites-trial/</loc>
<lastmod>2023-04-05T06:35:40+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/evaluation-of-daily-patch-application-duration-for-epicutaneous-immunotherapy-for-peanut-allergy/</loc>
<lastmod>2023-04-05T06:37:12+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/effect-of-epicutaneous-immunotherapy-vs-placebo-on-reaction-to-peanut-protein-ingestion-among-children-with-peanut-allergy/</loc>
<lastmod>2023-04-05T06:38:51+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/effect-of-varying-doses-of-epicutaneous-immunotherapy-vs-placebo-on-reaction-to-peanut-protein-exposure-among-patients-with-peanut-sensitivity/</loc>
<lastmod>2023-04-05T06:40:12+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/phase-3-trial-of-epicutaneous-immunotherapy-in-toddlers-with-peanut-allergy/</loc>
<lastmod>2023-06-14T12:43:31+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/impact-of-duration-of-wear-on-efficacy-of-epicutaneous-immunotherapy-with-viaskin-peanut-in-toddlers-aged-1-through-3-years-during-the-phase-3-epitope-study/</loc>
<lastmod>2023-06-14T12:47:10+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/efficacy-and-safety-of-epicutaneous-immunotherapy-for-peanut-allergy-in-subjects-aged-1-through-3-years-with-and-without-concomitant-asthma-in-the-epitope-study/</loc>
<lastmod>2023-06-16T05:39:54+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/recent-advances-in-epicutaneous-immunotherapy-and-potential-applications-in-food-allergy/</loc>
<lastmod>2024-03-04T11:09:01+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/safety-and-efficacy-of-epicutaneous-immunotherapy-with-dbv712-peanut-patch-in-peanut-allergy/</loc>
<lastmod>2024-03-04T11:14:28+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/epicutaneous-immunotherapy-with-viaskin-peanut-in-toddlers-a-plain-language-summary/</loc>
<lastmod>2024-03-04T11:15:55+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/varying-doses-of-epicutaneous-immunotherapy-with-viaskin-milk-vs-placebo-in-children-with-cows-milk-allergy-a-randomized-clinical-trial/</loc>
<lastmod>2024-04-03T14:43:49+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/epopex-epitope-open-label-extension-efficacy-and-safety-of-epicutaneousimmunotherapy-in-peanut-allergic-toddlers-after-3-years-of-treatment/</loc>
<lastmod>2025-01-10T11:07:27+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/vp250-average-daily-wear-time-impact-on-efficacy-and-safety-in-the-phase-3-epitope-study/</loc>
<lastmod>2025-01-10T11:22:40+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/changes-in-biomarkers-during-epicutaneous-immunotherapy-for-peanut-allergy-in-toddlers/</loc>
<lastmod>2025-01-10T11:22:45+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/efficacy-and-safety-of-epicutaneous-immunotherapy-in-peanut-allergic-toddlers-open-label-extension-to-epitope/</loc>
<lastmod>2025-03-18T16:57:49+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/real-world-protective-effects-of-peanut-epicutaneous-immunotherapy-in-allergic-toddlers/</loc>
<lastmod>2025-06-16T08:58:17+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/phase-2-study-to-evaluate-the-sensitivity-specificity-and-safety-of-dbv1605-as-a-diagnostic-tool-for-non-ige-mediated-cows-milk-allergy-in-children-aptitude/</loc>
<lastmod>2025-06-16T09:01:02+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/efficacy-and-safety-of-epicutaneous-immunotherapy-in-peanut-allergic-children-with-atopic-comorbidities/</loc>
<lastmod>2025-07-08T15:13:56+00:00</lastmod>
</url>			<url>
<loc>https://dbv-technologies.com/resource/long-term-safety-of-epicutaneous-immunotherapy-in-peanut-allergic-children-an-open-label-active-treatment-realise-study/</loc>
<lastmod>2025-07-08T15:16:28+00:00</lastmod>
</url>	</urlset>
